Strontium Ranelate Peptide Analog Explained
Strontium ranelate is essentially a dual-action repair agent for your bones and joints. People use it primarily for osteoporosis—when bones become fragile and brittle—but it's also being studied for arthritis because it appears to protect the cartilage in your joints. Think of your bones and joints like a building that's constantly being demolished and rebuilt. Most treatments only stop the demolition, but this peptide actually speeds up the reconstruction too.
Here's how it works: Your bones contain two types of cells working in opposite directions. One type (osteoblasts) builds new bone, while the other (osteoclasts) breaks down old bone to recycle it. The strontium in this peptide acts like a switch on your bone cells. It flips on the builders, telling them to create more bone material, while simultaneously telling the demolition crew to take it easier. In your joints, the strontium does something similar—it encourages your cartilage cells to produce more of the protective material that cushions your joints while reducing the enzymes that wear cartilage down. Recent clinical trials showed it actually slowed cartilage loss in osteoarthritis, which is remarkable because most treatments just manage pain rather than addressing the underlying damage.
Dosage Information
Typical Dose
2 g daily
Frequency
Once daily at bedtime
Administration
Oral granules dissolved in water
Half-Life
60 hours
Notes
Approved in EU for osteoporosis with restricted use due to cardiovascular risk. Not FDA-approved. Taken at bedtime away from food calcium and dairy which reduce absorption.
Why this matters
Long half-life; once-daily oral dosing for bone density.
Protocol cycle
Where does Strontium Ranelate Peptide Analog sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.73
Compound Data
Molecular Formula
C12H6N2O8SSr2
Molecular Weight
513.50 g/mol
IUPAC Name
distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate
PubChem CID
6918182Potential Side Effects
Strontium Ranelate Peptide Analog discussions
Quick Facts
- Administration
- Oral granules dissolved in water
- Typical Dose
- 2 g daily
- Frequency
- Once daily at bedtime
- References
- 0 curated + 50 from PubMed
- Clinical Trials
- 10 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Strontium Ranelate Peptide Analog
What is Strontium Ranelate Peptide Analog?
Strontium ranelate is a dual-action bone agent approved in Europe for osteoporosis that simultaneously inhibits bone resorption and stimulates bone formation — a unique mechanism that differentiates it from bisphosphonates which only inhibit resorption. It has been studied for osteoarthritis in addition to osteoporosis with clinical trial data showing reduced joint space narrowing and cartilage degradation markers suggesting disease-modifying effects. The strontium ion component has direct effects on chondrocyte biology making it relevant to joint health beyond its bone effects.
How does Strontium Ranelate Peptide Analog work?
Strontium ranelate works through the calcium-sensing receptor (CaSR) on bone cells and chondrocytes. On osteoblasts CaSR activation stimulates bone formation increasing bone mineral density. On osteoclasts strontium inhibits differentiation and activity reducing bone resorption. In cartilage chondrocytes strontium ranelate stimulates proteoglycan and type II collagen synthesis through CaSR-mediated signaling while reducing the production of cartilage-degrading metalloproteinases. Clinical trial data from the SEKOIA study showed significant reductions in joint space narrowing at the knee with strontium ranelate compared to placebo — one of the few positive DMOAD trials in osteoarthritis.
What is the recommended dosage for Strontium Ranelate Peptide Analog?
The typical dose is 2 g daily. Once daily at bedtime. Administration: Oral granules dissolved in water. Approved in EU for osteoporosis with restricted use due to cardiovascular risk. Not FDA-approved. Taken at bedtime away from food calcium and dairy which reduce absorption.
What are the side effects of Strontium Ranelate Peptide Analog?
Nausea and diarrhea (common initially). Cardiovascular risk — contraindicated in heart disease (serious — EU restriction). DRESS syndrome — severe drug hypersensitivity reaction (rare but serious). Venous thromboembolism risk (uncommon)
What is the Strontium Ranelate Peptide Analog cycle protocol?
Strontium Ranelate Peptide Analog is typically cycled continuous. Daily long-term therapy for osteoporosis management
Questions reflect common community inquiries. This is not medical advice.